


## Highlights of This Issue 1019

### REVIEW

- 1021** Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors  
Rodrigo Dienstmann, Jordi Rodon, Violeta Serra, and Josep Tabernero

### SMALL MOLECULE THERAPEUTICS

- 1032** Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer  
Niranjan Awasthi, Changhua Zhang, Anna M. Schwarz, Stefan Hinz, Margaret A. Schwarz, and Roderich E. Schwarz

- 1044**  The Phosphoinositide 3-Kinase  $\alpha$  Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells  
Elgilda Musi, Grazia Ambrosini, Elisa de Stanchina, and Gary K. Schwartz

- 1054** Centmitor-1, a Novel Acridinyl-Aceto-hydrazide, Possesses Similar Molecular Interaction Field and Antimitotic Cellular Phenotype as Rigosertib, ON 01910.Na  
Jenni H.E. Mäki-Jouppila, Leena J. Laine, Jonathan Rehnberg, Elli Narvi, Pekka Tiikkainen, Elvira Hukasova, Pasi Halonen, Arne Lindqvist, Lila Kallio, Antti Poso, and Marko J. Kallio

- 1067** Preclinical Evaluation of the Supercritical Extract of *Azadirachta Indica* (Neem) Leaves *In Vitro* and *In Vivo* on Inhibition of Prostate Cancer Tumor Growth  
Qiang Wu, Manish Kohli, H. Robert. Bergen III, John C. Cheville, R. Jeffrey Karnes, Hong Cao, Charles Y.F. Young, Donald J. Tindall, Mark A. McNiven, and Krishna Vanaja Donkena

- 1078** Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway  
Peiwen Yu, A. Douglas Laird, Xiangnan Du, Jianming Wu, Kwang-Ai Won, Kyoko Yamaguchi, Pin Pin Hsu, Fawn Qian, Christopher T. Jaeger, Wentao Zhang, Chris A. Buhr, Paula Shen, Wendy Abulafia, Jason Chen, Jenny Young, Arthur Plonowski, F. Michael Yakes, Felix Chu, Michelle Lee, Frauke Bentzien, Sanh Tan Lam, Stephanie Dale, David J. Matthews, Peter Lamb, and Paul Foster

- 1092** UPARANT: A Urokinase Receptor-Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and *In Vitro* and *In Vivo* Potency  
Maria Vincenza Carriero, Katia Bifulco, Michele Minopoli, Liliana Lista, Ornella Maglio, Luigi Mele, Gioconda Di Carluccio, Mario De Rosa, and Vincenzo Pavone

- 1105** Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models  
Xiaoping Zhang, Hua Lv, Qingyu Zhou, Rana Elkholi, Jerry E. Chipuk, M.V. Ramana Reddy, E. Premkumar Reddy, and James M. Gallo

- 1117**  Characterization of the Novel and Specific PI3K $\alpha$  Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials  
Christine Fritsch, Alan Huang, Christian Chatenay-Rivauday, Christian Schnell, Anupama Reddy, Manway Liu, Audrey Kauffmann, Daniel Guthy, Dirk Erdmann, Alain De Pover, Pascal Furet, Hui Gao, Stephane Ferretti, Youzhen Wang, Joerg Trappe, Saskia M. Brachmann, Sauveur-Michel Maira, Christopher Wilson, Markus Boehm, Carlos Garcia-Echeverria, Patrick Chene, Marion Wiesmann, Robert Cozens, Joseph Lehar, Robert Schlegel, Giorgio Caravatti, Francesco Hofmann, and William R. Sellers

- 1130** Protein Kinase D as a Potential Chemotherapeutic Target for Colorectal Cancer  
Ning Wei, Edward Chu, Peter Wipf, and John C. Schmitz

# Table of Contents

- 1142** **Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells**  
Warren Fiskus, Sunil Sharma, Jun Qi, John A. Valenta, Leasha J. Schaub, Bhavin Shah, Karissa Peth, Bryce P. Portier, Melissa Rodriguez, Santhana G.T. Devaraj, Ming Zhan, Jianting Sheng, Swaminathan P. Iyer, James E. Bradner, and Kapil N. Bhalla  
*See related article, p. 1194*
- 1155** **Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML *In Vitro* and *In Vivo***  
Katia Beider, Merav Darash-Yahana, Orly Blaier, Maya Koren-Michowitz, Michal Abraham, Hanna Wald, Ori Wald, Eithan Galun, Orly Eizenberg, Amnon Peled, and Arnon Nagler
- 1170** **The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks**  
Makiko Tahara, Takeshi Inoue, Futoshi Sato, Yasuyuki Miyakura, Hisanaga Horie, Yoshikazu Yasuda, Hirofumi Fujii, Kenjiro Kotake, and Kokichi Sugano
- 1181** **A Novel Temozolomide–Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells *In Vitro* and Intracranial Triple-Negative Tumor Growth *In Vivo***  
Thomas C. Chen, Hee-Yeon Cho, Weijun Wang, Manasi Barath, Natasha Sharma, Florence M. Hofman, and Axel H. Schönthal
- CANCER BIOLOGY AND SIGNAL TRANSDUCTION**
- 1194** **Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2**  
Suhu Liu, Sarah R. Walker, Erik A. Nelson, Robert Cerulli, Michael Xiang, Patricia A. Toniolo, Jun Qi, Richard M. Stone, Martha Wadleigh, James E. Bradner, and David A. Frank  
*See related article, p. 1142*
- 1206** **Embelin Reduces Colitis-Associated Tumorigenesis through Limiting IL-6/STAT3 Signaling**  
Yun Dai, Hongmei Jiao, Guigen Teng, Weihong Wang, Rongxin Zhang, Yunhong Wang, Lionel Hebbard, Jacob George, and Liang Qiao
- 1217** **Ponatinib Induces Apoptosis in Imatinib-Resistant Human Mast Cells by Dephosphorylating Mutant D816V KIT and Silencing  $\beta$ -Catenin Signaling**  
Bei Jin, Ke Ding, and Jingxuan Pan
- 1231** **PIM Kinases Are Essential for Chronic Lymphocytic Leukemia Cell Survival (PIM2/3) and CXCR4-Mediated Microenvironmental Interactions (PIM1)**  
Sarah Decker, Johannes Finter, Aaron James Forde, Sandra Kissel, Juerg Schwaller, Thomas Sebastian Mack, Anabel Kuhn, Nathanael Gray, Marie Follo, Hassan Jumaa, Meike Burger, Katja Zirlik, Dietmar Pfeifer, Chandrasekhar V. Miduturu, Hermann Eibel, Hendrik Veelken, and Christine Dierks
- 1246** **Pharmacologic Suppression of JAK1/2 by JAK1/2 Inhibitor AZD1480 Potently Inhibits IL-6-Induced Experimental Prostate Cancer Metastases Formation**  
Lei Gu, Pooja Talati, Paraskevi Vogiatzi, Ana L. Romero-Weaver, Junaid Abdulghani, Zhiyong Liao, Benjamin Leiby, David T. Hoang, Tuomas Mirtti, Kalle Alanen, Michael Zinda, Dennis Huszar, and Marja T. Nevalainen
- 1259** **Hedgehog Pathway Inhibition in Chondrosarcoma Using the Smoothened Inhibitor IPI-926 Directly Inhibits Sarcoma Cell Growth**  
Veronica T. Campbell, Puviindran Nadesan, S. Amanda Ali, Chang Ye Yale Wang, Heather Whetstone, Raymond Poon, Qingxia Wei, John Keilty, Jennifer Proctor, Lauren W. Wang, Suneel S. Apte, Karen McGovern, Benjamin A. Alman, and Jay S. Wunder
- 1270** **Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer**  
Mercedes Marín-Aguilera, Jordi Codony-Servat, Òscar Reig, Juan José Lozano, Pedro Luis Fernández, María Verónica Pereira, Natalia Jiménez, Michael Donovan, Pere Puig, Lourdes Mengual, Raquel Bermudo, Albert Font, Enrique Gallardo, María José Ribal, Antonio Alcaraz, Pere Gascón, and Begoña Mellado
- 1285** **Identification of Transmembrane Protein 98 as a Novel Chemoresistance-Confering Gene in Hepatocellular Carcinoma**  
Kevin Tak-Pan Ng, Chung Mau Lo, Dong Yong Guo, Xiang Qi, Chang Xian Li, Wei Geng, Xiao Bing Liu, Chang Chun Ling, Yuen Yuen Ma, Wai Ho Yeung, Yan Shao, Ronnie Tung-Ping Poon, Sheung Tat Fan, and Kwan Man

# Table of Contents

- 1298** **Aurora Kinase Inhibition Induces PUMA via NF- $\kappa$ B to Kill Colon Cancer Cells**  
Jing Sun, Kyle Knickelbein, Kan He, Dongshi Chen, Crissy Dudgeon, Yongqian Shu, Jian Yu, and Lin Zhang
- 1309** **Nuclear Translocation of Hand-1 Acts as a Molecular Switch to Regulate Vascular Radiosensitivity in Medulloblastoma Tumors: The Protein uPAR Is a Cytoplasmic Sequestration Factor for Hand-1**  
Swapna Asuthkar, Venkateswara Rao Gogineni, Jasti S. Rao, and Kiran Kumar Velpula
- 1323** **The G Protein–Coupled Receptor GALR2 Promotes Angiogenesis in Head and Neck Cancer**  
Rajat Banerjee, Elizabeth A. Van Tubergen, Christina S. Scanlon, Robert Vander Broek, Joel P. Lints, Min Liu, Nickole Russo, Ronald C. Inglehart, Yugang Wang, Peter J. Polverini, Keith L. Kirkwood, and Nisha J. D’Silva
- 1334** **The Role of Gene Body Cytosine Modifications in *MGMT* Expression and Sensitivity to Temozolomide**  
Erika L. Moen, Amy L. Stark, Wei Zhang, M. Eileen Dolan, and Lucy A. Godley
- 1345** **ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models**  
Li Zhang, Carla Castanaro, Bo Luan, Katie Yang, Liangfen Fan, Jeanette L. Fairhurst, Ashique Rafique, Terra B. Potocky, Jing Shan, Frank J. Delfino, Ergang Shi, Tammy Huang, Joel H. Martin, Gang Chen, Douglas MacDonald, John S. Rudge, Gavin Thurston, and Christopher Daly
- 1356** **Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer**  
Toni M. Brand, Mari Iida, Emily F. Dunn, Neha Luthar, Kellie T. Kostopoulos, Kelsey L. Corrigan, Matthew J. Wleklinski, David Yang, Kari B. Wisinski, Ravi Salgia, and Deric L. Wheeler
- 1369** **Metallothionein 1G and Zinc Sensitize Human Colorectal Cancer Cells to Chemotherapy**  
Juan M. Arriaga, Angela Greco, José Mordoh, and Michele Bianchini


## COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

- 1382** **Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer**  
Funda Meric-Bernstam, Garrett M. Frampton, Jaime Ferrer-Lozano, Roman Yelensky, Jose A. Pérez-Fidalgo, Ying Wang, Gary A. Palmer, Jeffrey S. Ross, Vincent A. Miller, Xiaoping Su, Pilar Eroles, Juan Antonio Barrera, Octavio Burgues, Ana M. Lluch, Xiaofeng Zheng, Aysegul Sahin, Philip J. Stephens, Gordon B. Mills, Maureen T. Cronin, and Ana M. Gonzalez-Angulo

 AC icon indicates Author Choice


For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

# Table of Contents



## ABOUT THE COVER

Angiogenesis is important for tumor progression. In squamous cell carcinoma of the head and neck (SCCHN), angiogenesis is activated by cytokines including IL-6 and VEGF. Galanin receptor 2 (GALR2) is a G protein-coupled receptor that induces aggressive growth in SCCHN. GALR2 stimulates tumor angiogenesis in SCCHN via p38-mediated inhibition of tristetraprolin (TTP) with resultant enhanced cytokine secretion. Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN. For details, see article by Banerjee, Van Tubergen, and colleagues on page 1323.



# Molecular Cancer Therapeutics

**13 (5)**

*Mol Cancer Ther* 2014;13:1019-1389.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/13/5>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/13/5>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.